Hap Trading, LLC Blueprint Medicines Corp Call Options Transaction History

Hap Trading, LLC

8 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2020 Nov 13, 2020	SELL	$66.45 - $92.7 $19,935 - $27,810	-300 Reduced 0.48%	61,600 $1.71 Million
Q2 2020 Aug 10, 2020	BUY	$57.09 - $79.27 $2.78 Million - $3.86 Million	48,700 Added 368.94%	61,900 $1.09 Million
Q1 2020 May 08, 2020	SELL	$48.11 - $82.22 $283,849 - $485,098	-5,900 Reduced 30.89%	13,200 $30,000
Q4 2019 Feb 11, 2020	BUY	$66.73 - $82.59 $1.27 Million - $1.58 Million	19,100 New	19,100 $88,000
Q3 2018 Nov 09, 2018	SELL	$58.91 - $78.32 $5.92 Million - $7.87 Million	-100,500 Closed	0 $0
Q2 2018 Aug 13, 2018	BUY	$60.96 - $101.18 $4.57 Million - $7.59 Million	75,000 Added 294.12%	100,500 $34,000
Q1 2018 May 11, 2018	BUY	$73.28 - $102.95 $7,328 - $10,295	100 Added 0.39%	25,500 $105,000
Q4 2017 Feb 09, 2018	BUY	$62.91 - $88.32 $1.6 Million - $2.24 Million	25,400	25,400 $96,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Hap Trading, LLC, based on Form 13F filings with the SEC.

Stay updated on Hap Trading, LLC with notifications on news.